On June 27, 2023 Disruptive Pharma reported the company is initiating the development of MMC sorafenib as its first proprietary product based on the mesoporous magnesium carbonate (MMC) platform (Press release, Disruptive Pharma, JUN 27, 2023, View Source [SID1234649943]). Sorafenib is a cornerstone in the treatment of patients suffering from hepatocellular- and renal cell carcinomas. While highly efficacious, currently approved formulations also exhibit undesirable side effects. With Disruptive Pharma’s MMC platform we could demonstrate bioequivalence using significantly reduced quantities of the active pharmaceutical ingredient (API). In our upcoming clinical program, we aim to translate the sorafenib dose reduction advantage into intra-patient variability and potentially other patient benefits.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mesoporous magnesium carbonate (MMC) is Disruptive Pharma’s proprietary drug delivery platform for amorphous stabilization and solubility enhancement. MMC leverages a uniformly porous structure to stabilize small molecule APIs into an amorphous state. Its unique properties make MMC an ideal carrier for APIs and its template-free synthesis allows for facilitated production scale-up.